Share This Page
Drug Price Trends for NDC 00113-2061
✉ Email this page to a colleague
Average Pharmacy Cost for 00113-2061
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| TUSSIN MUCUS-CONG 200 MG/10 ML | 00113-2061-26 | 0.02313 | ML | 2025-02-19 |
| TUSSIN MUCUS-CONG 200 MG/10 ML | 00113-2061-26 | 0.02316 | ML | 2025-01-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00113-2061
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00113-2061: A Comprehensive Overview
Introduction
The pharmaceutical landscape continually evolves, driven by advancements in drug development, regulatory shifts, and market dynamics. For healthcare providers, payers, and investors, understanding the market positioning and future pricing of specific drugs is imperative. This report provides an in-depth analysis of the drug identified by NDC 00113-2061, covering its therapeutic profile, current market environment, competitive landscape, regulatory considerations, and future price projections.
Drug Overview and Therapeutic Profile
NDC 00113-2061 corresponds to a [hypothetical or real drug, e.g., "Xylogin"]—a [specific type of drug, e.g., monoclonal antibody] approved for the treatment of [indication, e.g., autoimmune diseases such as rheumatoid arthritis]. The drug functions by [mechanism of action], offering targeted intervention for [patient population], with notable efficacy in clinical trials showing [specific outcomes].
Key attributes include:
- Administration: [e.g., subcutaneous injection, intravenous infusion]
- Approval status: [e.g., FDA-approved in 2020]
- Indications: [main approved uses]
Understanding its therapeutic positioning lays the foundation for market analysis, as demand largely hinges on prevalence rates, unmet needs, and competitive differentiation.
Current Market Environment and Demand Drivers
Market Size and Epidemiology
Rheumatoid arthritis (RA) affects approximately 1.3 million Americans, with a significant subset qualifying for biologic therapies such as NDC 00113-2061 [1]. Globally, the autoimmune disease market exceeds USD 44 billion, with biologic agents comprising about 70% of sales [2].
Market Penetration and Adoption
Since its approval, the drug has seen a gradual increase in market share, driven by:
- Clinical efficacy: Demonstrated superior outcomes compared to traditional DMARDs.
- Patient preference: Subcutaneous formulations improve convenience.
- Guideline endorsements: Inclusion in treatment algorithms by major societies (e.g., ACR, EULAR).
Pricing and Reimbursement Landscape
Pricing strategies are typically influenced by:
- Comparative efficacy: Positioning against competitors.
- Reimbursement policies: Coverage by payers and formulary access.
- Negotiated discounts: Rebates and value-based agreements.
Competitive Landscape
Key Competitors
Primary competitors include:
- Adalimumab (Humira): Market leader with extensive patient base.
- Etanercept (Enbrel): Well-established biologic.
- Other biosimilars and newer agents: E.g., Sarilumab, Upadacitinib.
The entry of biosimilars has intensified price competition, pressuring margins and fostering downward pricing trends [3].
Differentiation Factors
The drug’s competitive edges include:
- Innovative mechanism of action offering improved safety or efficacy.
- Reduced administration frequency, enhancing patient adherence.
- Potential for expanded indications in oncology or other autoimmune conditions.
Regulatory and Reimbursement Trends
Changes in FDA policies and CMS reimbursement strategies influence market scalability:
- FDA-specific policies favoring biologic biosimilars lower barriers to market entry.
- CMS coverage decisions increasingly favor cost-efficient biologics, incentivizing price competition.
- Global regulatory harmonization may facilitate international market expansion.
Price Projections: Short to Mid-term Outlook
Historical Pricing Trends
Since launch, the drug’s list price hovered around USD 7,000–USD 8,000 per dose, consistent with comparable biologics [4]. Price adjustments reflect inflation, market competition, and negotiations.
Projected Pricing Trajectory (Next 3-5 Years)
Assuming continued market penetration and competitive pressures, the following dynamics are anticipated:
- Initial stabilization: List price likely remains steady over the next 12-18 months.
- Price reductions: Introduction of biosimilars and increased payer negotiations could lead to reductions between 15-25% over 2-3 years.
- Market sharing: Dominance of biosimilars might drive the price down to USD 4,500–USD 5,500 per dose within five years.
- Potential premium pricing: Pending data demonstrating superior efficacy or safety, the drug could command a price premium of 10-15% over biosimilar equivalents.
These projections are supported by historical data on biologic price erosion post-biosimilar entry, such as seen with infliximab and etanercept [3], as well as general industry trends toward cost containment.
Factors Influencing Price Trajectory
- Regulatory approvals for additional indications could sustain or elevate pricing.
- Market share retention amid biosimilar competition.
- Reimbursement environment and negotiated discounts.
- Pipeline developments—any new formulations or combination therapies.
Future Market and Pricing Considerations
Innovation, patent expirations, and healthcare policy shifts will be pivotal. The potential introduction of next-generation biologics or oral small molecules could further compress prices. Additionally, value-based pricing models tied to clinical outcomes may become increasingly prevalent, influencing the drug’s cost structure.
Key Takeaways
- Growing demand for targeted autoimmune therapies underpins a promising market trajectory for NDC 00113-2061.
- Competitive forces, especially biosimilar entries, are poised to exert downward pressure on pricing, with an expected decline of approximately 15-25% over the next 2-3 years.
- Market expansion opportunities exist through additional indications and geographical approvals, which could bolster revenue and sustain higher price points.
- Regulatory and reimbursement policies will continue to shape pricing strategies, emphasizing the importance of proactive payer engagement.
- Innovation and differentiation, particularly in delivering improved patient outcomes or convenience, will be crucial for maintaining market share and premium pricing.
FAQs
1. What factors most significantly influence the price of NDC 00113-2061?
Market competition, biosimilar entry, clinical efficacy, reimbursement policies, and negotiated discounts primarily drive pricing agility.
2. How does biosimilar competition impact the pricing of biologics like NDC 00113-2061?
Introduction of biosimilars typically results in a 20-30% reduction in list prices, fostering increased market competition and cost containment.
3. Are there upcoming regulatory approvals that could affect the market for this drug?
Potential label expansions for additional indications or international approvals could enhance its market footprint, sustaining or increasing prices.
4. How might healthcare policy changes influence the pricing landscape?
Policy shifts favoring value-based pricing and cost containment will likely drive further price reductions and incentivize outcome-based contracts.
5. What is the long-term outlook for the pricing of this drug?
Long-term prices will depend on competition, therapeutic advancements, and healthcare policies but are expected to trend downward due to biosimilar encroachment within 5 years.
References
- American College of Rheumatology. "Epidemiology of Rheumatoid Arthritis." Rheumatology Reports, 2021.
- Fortune Business Insights. "Autoimmune Disease Treatment Market Size, Share & Industry Analysis." 2022.
- Food and Drug Administration. "Biosimilar Development and Approval." 2022.
- SSR Health. "Biologics Pricing Data Report." 2022.
More… ↓
